CHANGE-seq™
Nomination assay
CHANGE-seq and CHANGE-seq-BE are sensitive, genome-wide, high-throughput biochemical assays for off-target site nomination. In both methods, circularized genomic DNA is treated in vitro with the editor of interest, followed by selective sequencing of edited on- and off-target sites. By combining CHANGE-seq-BE and ONE-seq-BE, SeQure offers the only off-target nomination service that delivers orthogonal assays for base editors that align with the FDA’s recommendations for off-target site nomination in genome-editing therapies.
CHANGE-seq overview
CHANGE-seq & CHANGE-seq-BE
Biochemical off-target nomination assay optimized for CRISPR-Cas and base editing applications. Designed to be paired with ONE-seq or ONE-seq-BE as an orthogonal method. CHANGE-seq and CHANGE-seq-BE enable selective sequencing of in vitro-cleaved genomic DNA.
- Compatible with Cas9, Cas12a, ABE, CBE
- Sensitive biochemical nomination assay
Off-target nomination
Early discovery - gRNA/editor selection
CTA/IND-enabling
Related nomination assays
From early discovery through pre-clinical and clinical development
